Introduction: Beyond the Extrapyramidal System {#section1-1073858418807887}
==============================================

Until the early 1970s, medical practitioners were being taught that the striatum (caudate and putamen nuclei) is part of the extrapyramidal motor system and exerts a "steadying influence" ([@bibr207-1073858418807887]) on lower motor neurons via a putative descending projection ([@bibr58-1073858418807887]; [@bibr118-1073858418807887]). As a result of research conducted over the next two decades, in what may be called the Golden Age of basal ganglia (BG) research, this vague and imprecise description was supplanted in medical and neuroscience textbooks by the *direct* versus *indirect* pathway model (also known as the "box-and-arrow" model) of BG physiology and pathophysiology ([@bibr4-1073858418807887]; [@bibr55-1073858418807887]). This model organized what had been learned during this period about the gross anatomy and physiology of the BG into a comprehensive model of how two mutually antagonistic pathways gate action and how movement disorders could be conceptualized as resulting from an imbalance between them.

The Golden Age of Basal Ganglia Research and the "Box-and-Arrow" Model {#section2-1073858418807887}
======================================================================

The box-and-arrow model ([Fig. 1A](#fig1-1073858418807887){ref-type="fig"}) (in which each of the various BG nuclei is represented as a box, and the synaptic connections among them as arrows) is the product of discoveries made from the mid-1970s to the early 1990s by several research groups ([@bibr6-1073858418807887]; [@bibr44-1073858418807887]; [@bibr45-1073858418807887]; [@bibr61-1073858418807887]; [@bibr81-1073858418807887]; [@bibr96-1073858418807887]; [@bibr119-1073858418807887]; [@bibr153-1073858418807887]; [@bibr181-1073858418807887]). These findings revealed novel and previously unknown principles of the BG's structure and function. The most influential finding pertained to the striatum, the main input structure of the BG. Anatomical tracing studies revealed that GABAergic spiny projection neurons (SPNs), which, in rodents, account for over 95% of striatal neurons, could be divided into two equally sized populations based on their axonal projections ([@bibr44-1073858418807887]; [@bibr117-1073858418807887]; [@bibr153-1073858418807887]; [@bibr157-1073858418807887]). The axonal arborizations of the first population projected to one or both of the output structures of the BG: the substantia nigra pars reticulata (SNr) and the internal segment of the globus pallidus (GPi; entopeduncular nucleus in rodents). These neurons are referred to as direct pathway SPNs (dSPNs), because their axons project *directly* to the output nuclei, in addition to local striatal targets and the external segment of the globus pallidus (GPe, or simply GP in rodents). The second population of SPNs projected only to local striatal targets and the GPe and came to be known as indirect-pathway SPNs (iSPNs). Most dSPNs also contain the neuropeptides dynorphin and substance P, whereas most iSPNs contain the neuropeptide enkephalin ([@bibr18-1073858418807887]).

![(A) The original Box-and-Arrow model, reformatted. (B) An updated model includes the thalamostriatal, subthalamopallidal (STN → GPe), pallidostriatal and pallidocortical pathways ([@bibr173-1073858418807887]) as well as striatal interneurons and collaterals. d/iSPNs, direct/indirect pathway spiny projection neurons; GPe/i, external/internal segments of the globus pallidus; SNc/r, substantia nigra pars compacta/reticulata; SC, superior colliculus; INs, striatal interneurons; D~1~R/D~2~R, dopamine D~1~/D~2~ receptors; FC, frontal cortex; ACh, acetylcholine.](10.1177_1073858418807887-fig1){#fig1-1073858418807887}

Another principle of BG function that was elaborated upon during this period is that of disinhibition---the process by which the target of an autonomously active population of inhibitory neurons is released from tonic inhibition when the inhibitory neurons are themselves inhibited ([@bibr45-1073858418807887]). Work in non-human primates subsequently demonstrated that GABAergic SNr neurons tonically inhibit neurons in the superior colliculus (SC). Inhibition of SNr neurons by dSPNs disinhibits the SC, enabling the generation of saccades ([@bibr211-1073858418807887]). Thus, a model of how the BG gates action began to emerge. Activation of the feedforward direct pathway, comprised of dSPNs inhibiting SNr/GPi neurons, disinhibits the targets of the BG (e.g., SC and thalamus) to enable movement. The direct pathway, thus, became known as the "GO" pathway of the BG.

At around the same time, subthalamic nucleus (STN) neurons were recognized to be glutamatergic and generate monosynaptic excitatory postsynaptic potentials (EPSPs) in SNr neurons ([@bibr119-1073858418807887]; [@bibr147-1073858418807887]). Because STN neurons receive GABAergic input from the GPe and project to the GPi/SNr, it was concluded that the indirect pathway (iSPNs to GPe to STN to GPi/SNr) forms a "dis-disinhibitory" (equivalent to an inhibitory) pathway, ultimately disinhibiting GPi/SNr output and suppressing movement. The indirect pathway came to be known as the "NO-GO" pathway of the BG.

The pinnacle of the formulation of the box-and-arrow model was the discovery that dSPNs and iSPNs can also be distinguished by their surface expression of dopamine receptors: dSPNs express D~1~ receptors (D~1~Rs), which generally enhance neuronal excitability, whereas iSPNs express D~2~ receptors (D~2~Rs), which generally reduce neuronal excitability ([@bibr81-1073858418807887]; [@bibr80-1073858418807887]). This distinction provided a straightforward explanation for the facilitating action of dopamine in the striatum. When dopamine is released in the striatum, it activates D~1~Rs on dSPNs to increase activation of the direct pathway and D~2~Rs on iSPNs to decrease activation of the indirect pathway, biasing the BG toward a "GO" state. By the same logic, it was argued that when dopamine is depleted, as in Parkinson's disease (PD), the BG would be biased toward a perpetual "NO-GO" state, which could explain the *hypokinetic* nature of PD ([Fig. 2](#fig2-1073858418807887){ref-type="fig"}). Using a similar argument (but independent of dopamine) the box-and-arrow model could also account for Huntington's disease (HD), characterized by involuntary hyperkinetic choreic movements and a massive loss of SPNs. A preferential loss of iSPNs in early stages of HD would presumably weaken the indirect pathway and bias the network toward a perpetual "GO" (i.e., choreic) state, wherein the output nuclei of the BG are underactive ([Fig. 3](#fig3-1073858418807887){ref-type="fig"}).

![Parkinson's disease (PD). Loss of dopamine weakens the direct pathway and strengthens the indirect pathway, leading to elevated inhibitory outflow from the basal ganglia (BG).](10.1177_1073858418807887-fig2){#fig2-1073858418807887}

![Huntington's disease (HD). Preferential loss of indirect pathway spiny projection neurons (iSPNs) leads to relative overactivation of the direct pathway, leading to decreased inhibitory outflow from the basal ganglia (BG).](10.1177_1073858418807887-fig3){#fig3-1073858418807887}

Thus, the strength of the box-and-arrow model was in its ability to explain changes in the basal firing rates of neurons within the various BG nuclei, which in turn presumably explains the hypokinetic and hyperkinetic motor symptoms of PD (e.g., akinesia/bradykinesia) and HD (e.g., hyperkinesia/chorea in early stages and hypokinesia/bradykinesia in late stages). Because tremors, which are a cardinal symptom of PD, are dynamic by nature, no attempt was made initially to use the box-and-arrow model to explain them. However, if the circuit or loop structure of the box-and-arrow model is taken into consideration, ideas from control theory can show that rhythmic activity can easily arise in these models as destabilization of a negative feedback loop, which could in turn explain tremorgenesis (see [Box 1](#boxed-text1-1073858418807887){ref-type="boxed-text"}). Nevertheless, showing a causal relationship between pathological oscillations and tremor has proved tricky.

###### 

Oscillations and synchrony in the basal ganglia (BG): A dynamical extension of the box-and-arrow model.

At about the time of the formulation of the box-and-arrow model, studies began to show that neural activity in the cortico-BG circuits of human PD patients and animals with experimental parkinsonism exhibited abnormal oscillatory patterns of activity in the theta (5-8 Hz) and beta (15-40 Hz) ranges ([@bibr22-1073858418807887]; [@bibr28-1073858418807887]; [@bibr89-1073858418807887]; [@bibr93-1073858418807887]; [@bibr106-1073858418807887]; [@bibr107-1073858418807887]; [@bibr133-1073858418807887]; [@bibr135-1073858418807887]; [@bibr142-1073858418807887]; [@bibr148-1073858418807887]; [@bibr168-1073858418807887]). Because resting tremor is one of the cardinal symptoms of the disease, it was tacitly assumed that the oscillatory activity in the BG must cause the tremor, although this has never been demonstrated convincingly. Moreover, there is evidence that brain regions, such as the cerebellum, that are not part of the cortico-BG circuit, are implicated in the tremor as well ([@bibr209-1073858418807887]). Nevertheless, the discovery of these oscillations sparked interest in the hypothesis that the known BG circuitry---as reflected in the box-and-arrow model---could in and of itself give rise to oscillations. This hypothesis was buttressed by a seminal article by Dietmar Plenz and Steve Kitai ([@bibr160-1073858418807887]) that demonstrated the spontaneous generation of oscillatory activity in the STN and GP in the lower and sub-delta (0.5-2 Hz) range in an organotypic co-culture of cortex, striatum, STN and GP. Importantly, they demonstrated that it was the sub-circuit comprised of the reciprocally connected GP and STN in the culture that was necessary for the generation of oscillations ([Fig. 1B](#fig1-1073858418807887){ref-type="fig"}). Note that the reciprocal connection between the GP and STN was entirely absent from the box-and-arrow model ([Fig. 1A](#fig1-1073858418807887){ref-type="fig"}). We now know that the capacity of this sub-circuit to generate oscillations is related to the fact that GP and STN neurons are themselves autonomous pacemakers. Thus, their reciprocal excitatory (STN to GP) and inhibitory (GP to STN) inputs create something akin to a central pattern generator, whose ability to generate rhythmic output arises from a similar excitatory--inhibitory coupling of autonomously bursting neurons in the spinal cord ([@bibr25-1073858418807887]; [@bibr156-1073858418807887]; [@bibr194-1073858418807887]). Incidentally, because many neuronal types in the BG are autonomous pacemakers, including dopaminergic SNc neurons and some striatal interneurons (see [Box 2](#boxed-text2-1073858418807887){ref-type="boxed-text"}), the study of mechanisms of robust pacemaking has become one of the central themes of BG research for both experimentalists and modelers ([@bibr12-1073858418807887]; [@bibr42-1073858418807887]; [@bibr41-1073858418807887]; [@bibr98-1073858418807887]; [@bibr188-1073858418807887]; [@bibr203-1073858418807887]), and has given us new insights into how channelopathies that affect pacemaking contribute to the pathophysiology of PD and other BG-related movement disorders ([@bibr13-1073858418807887]; [@bibr41-1073858418807887]; [@bibr40-1073858418807887]; [@bibr203-1073858418807887]).

While the GP-STN circuit is widely thought to be the driver of abnormal oscillatory activity in the BG, recent work by Nicolas Mallet has shown that this cannot be the entire story. As mentioned above the appearance of beta band oscillations is a hallmark of PD and experimental parkinsonism. In a very elegant study, he used optogenetics to silence neural activity in various BG structures in hemi-parkinsonian mice *in vivo* (where dopaminergic neurons were destroyed chemically only in one hemisphere). He found that the beta band activity was abolished only when GP activity was silenced, but not when the STN was silenced (N. Mallet, personal communication), which argues against the GP-STN sub-circuit as the driver of parkinsonian beta oscillations.

An alternative hypothesis is that rhythmogenesis can be conceived as arising from a delayed negative-feedback loop composed of the entire cortico-BG circuit, with the delays arising from lags in polysynaptic transmission and integration. Control theory predicts that delayed feedback loops can become destabilized if the gain in the circuit is too high. A day-to-day analogy is the procedure of adjusting the heat of the hot-water tap for a shower. If the boiler is positioned far away from shower tap (hence the delay), it will take a few cycles of "too cold"/"too hot" to get it just right. The ability to change the gain of the adjustment (make smaller and smaller corrections with the tap) make it possible to reach a desired comfortable level with only a few cycles of over- and undershooting. Now, if the person in the shower is incapable of making small adjustments (i.e., her gain is too high) she could find herself incapable of reaching a stable fixed temperature but instead experiencing a never-ending oscillation between "too hot" and "too cold."

A hypothesis originally proposed by one of us ([@bibr91-1073858418807887]) is that the imbalance between the direct and indirect pathways in PD results in an increased gain along the circuit which gives rise to oscillations ([@bibr129-1073858418807887]). To see this, we consider the box-and-arrow circuit in the parkinsonian state. As described in the accompanying figure, the circuit can be reduced to a two-population network where "cortex" represents thalamocortical circuitry and where the entire multisynaptic pathway leading from the cortex to the GPi is collapsed to a single effectively excitatory link from "cortex" to GPi. The assumption is that the imbalance between the direct and indirect pathways that occurs in PD translates to an increase in the effectively positive gain along this pathway. Under these circumstances the "cortex" and GPi settle in an out-of-phase oscillation. The effective cortical excitation reaches the GPi with a delay (e.g., half a cycle late). The resulting excitation of GPi increases the inhibition returned to the "cortex". This causes the previous cortical excitation to wane, which in turn reduces the excitation of the GPi. The GPi then disinhibits the "cortex", and so the "cortex" excites the GPi again. This process repeats *ad infinitum* resulting in stable rhythmic oscillations.

Another dynamical property of BG activity that has become a hallmark of parkinsonism is the appearance of abnormal synchronous activity throughout the cortico-BG circuitry in both human and non-human primates ([@bibr89-1073858418807887]; [@bibr93-1073858418807887]; [@bibr148-1073858418807887]; [@bibr168-1073858418807887]). It is possible that abnormal synchrony, particularly in the output from motor cortex ([@bibr59-1073858418807887]; [@bibr89-1073858418807887]; [@bibr154-1073858418807887]), ultimately co-activates antagonistic muscles and thus underlies akinesia and cogwheel muscle rigidity that are hallmarks of PD ([@bibr89-1073858418807887]). The appearance of abnormal synchrony in the GP is particularly remarkable, given that in healthy individuals the neural activity of GP neurons is found to be entirely decorrelated, despite the large convergence of inputs to the GP from the striatum and the STN. It is currently believed that collective GP activity is actively decorrelated ([@bibr88-1073858418807887]; [@bibr202-1073858418807887]), with the purpose of optimizing information compression and transfer and the maintenance of distinct information channels that course through the GP. The loss of this active decorrelation is thought to contribute to the pathophysiology of PD. It has even been proposed that the therapeutic action of deep brain stimulation is achieved by restoring the decorrelated state and disrupting abnormal synchrony ([@bibr203-1073858418807887]).

![Cortico-basal ganglia oscillations in the box-and-arrow model of Parkinson's disease (PD). (A) Box-and-arrow diagram for PD, including the recurrent connections between the subthalamic nucleus (STN) and external segment of the globus pallidus (GPe), which are considered a possible driver of parkinsonian oscillations (the weakened cortex-STN link ([@bibr46-1073858418807887]) is omitted). (B) Same network after subsuming the thalamus into the cortex (both are excitatory) and after subsuming the indirect pathway into an effective excitatory direct pathway that is enhanced in PD. (C) Further collapsing the direct and indirect pathway and the striatum as a whole into a *delayed* excitatory cortex-GPi (GPi is the internal segment of the globus pallidus) link whose gain is elevated relative to the normal condition. (D) Increasing the gain in a simplified basal ganglia (BG) network (at *t* = 250 ms) can give rise to oscillations due to synaptic delays along the entire cortico-BG circuit.](10.1177_1073858418807887-fig5){#fig5-1073858418807887}

In summary, the conceptually simple, elegant, evidence-based box-and-arrow model provided a first theoretical framework to (a) explain the collective action of the BG in health and disease ([@bibr4-1073858418807887]; [@bibr55-1073858418807887]), (b) generate testable experimental predictions ([@bibr22-1073858418807887]; [@bibr27-1073858418807887]; [@bibr50-1073858418807887]; [@bibr74-1073858418807887]; [@bibr123-1073858418807887]) and (c) be readily taught to the next generation of neuroscientists and medical practitioners. Most important, it helped establish functional neurosurgery as a justifiable method to normalize the mean activity of the various BG nuclei in disease states ([@bibr21-1073858418807887]; [@bibr29-1073858418807887]; [@bibr136-1073858418807887]). Indeed, deep brain stimulation of targeted BG nuclei has helped over a hundred thousand patients worldwide since the early 1990s ([@bibr165-1073858418807887]). For these reasons, the box-and-arrow model has become the prevailing dogma in the field, which adorns medical and neuroscience textbooks ([@bibr23-1073858418807887]; [@bibr184-1073858418807887]).

Over the course of the two and a half decades since the formulation of the box-and-arrow model, our knowledge of BG anatomy, biochemistry, circuitry, and physiology has expanded, giving us new insights into the pathogenesis of BG-related movement disorders and elucidating key predictive limitations of the original model. Although many transformative discoveries have been made throughout the field, our focus here will be on the striatum, in particular the dorsal striatum, which is associated with motor behavior. In particular, we focus on two areas in which there have been great strides in understanding the structure and function of the striatum: striatal microcircuitry and synaptic plasticity. In each case, we will reference various movement disorders (with an emphasis on PD and HD) to demonstrate how the current conceptualization of striatal pathophysiology is related to maladaptive changes in striatal circuit function.

The Striatum: The Heart of the Box-and-Arrow Model {#section3-1073858418807887}
==================================================

The striatum can be considered the heart of the box-and-arrow model. Since it houses all dSPNs and iSPNs, it is the site of the initial divergence of the direct and indirect pathways and is where dopamine acts to facilitate action ([@bibr5-1073858418807887]; [@bibr81-1073858418807887]; [@bibr80-1073858418807887]; [@bibr189-1073858418807887]; [@bibr197-1073858418807887]). It is also where dopamine depletion causes circuit changes thought to lead to the hypokinetic symptoms of PD and where the selective dysfunction and ultimate loss of iSPNs is thought to underlie early-stage HD ([@bibr4-1073858418807887]; [@bibr55-1073858418807887]; [@bibr164-1073858418807887]; [@bibr170-1073858418807887]). Both effects have been attributed to an "imbalance" between the direct and indirect pathways (see [Figs. 2](#fig2-1073858418807887){ref-type="fig"} and [3](#fig3-1073858418807887){ref-type="fig"}). Studies using optogenetic techniques (i.e., the selective expression of light activated ion channels in mammalian tissue and transgenic mouse lines in a cell-type specific manner) to selectively activate either the direct or the indirect pathway in freely moving mice have lent support to the overall antagonistic nature of these pathways both in health and disease ([@bibr123-1073858418807887]). However, such forced activation of striatal pathways is akin to restricting a pianist to strike two chords: one composed of all the white keys and the other of all the black keys. Such a manipulation would eradicate any finesse in the neural output of the striatum. Indeed, recent studies have clearly demonstrated that dSPNs and iSPNs are co-activated during normal motor behavior in freely moving mice and cannot be perceived as strictly antagonistic to each other ([@bibr50-1073858418807887]).

The arrows representing striatal output in the model are encoded exclusively by GABAergic SPNs, the activity of which is constrained and shaped by the complex microcircuity described in the boxes and text of this review (and much of which is not represented in the box-and-arrow model). There are many factors that determine the relative weights of the diagrammatic arrows in [Figure 1A](#fig1-1073858418807887){ref-type="fig"}, including the biophysical properties of dSPNs and iSPNs themselves and the synaptic strength of their afferent inputs. The first thing that should be noted is that iSPNs are intrinsically more excitable than dSPNs, suggesting that there is an innate aptitude for imbalanced striatal output ([@bibr37-1073858418807887]; [@bibr83-1073858418807887]; [@bibr125-1073858418807887]). Alterations in SPN intrinsic excitability are common in disorders involving the striatum. For example, one of the most robust physiological alterations in genetic mouse models of HD is an increase in SPN input resistance ([@bibr68-1073858418807887]; [@bibr121-1073858418807887]; [@bibr164-1073858418807887]). The net effect is to make SPNs more excitable. This increase in input resistance may predominantly occur in dSPNs ([@bibr167-1073858418807887]), thus biasing striatal output toward the direct pathway, consistent with hyperlocomotion associated with chorea. Changes in intrinsic excitability also occur in PD models, which will be discussed below.

The second thing to note about SPN physiology is that both dSPNs and iSPNs have remarkably hyperpolarized resting membrane potentials, near −90mV, which is due to the inward rectifying potassium channel they express ([@bibr80-1073858418807887]; [@bibr178-1073858418807887]; [@bibr205-1073858418807887]). What this means is that SPNs are quiescent at rest and require substantial excitatory synaptic drive to approach spike threshold and fire action potentials. Therefore, in the absence of afferent stimulation, the striatum can essentially be thought of as "silent," imposing no inhibitory cues on the downstream nuclei of the basal ganglia. SPNs require coordinated, converging synaptic activation to overcome their hyperpolarized resting membrane potential and fire action potentials ([@bibr92-1073858418807887]; [@bibr185-1073858418807887]; [@bibr205-1073858418807887]).

How does converging excitatory input drive SPN output? Early studies in rodents observed that bouts of converging synaptic activation likely originating from the cortex can depolarize SPNs from their silent hyperpolarized resting membrane potential (referred to as the "down state") to a depolarized "up state" from which action potentials can fire. While these states were first discovered in non-anesthetized animals, the particular anesthesia influences their shape and duration ([@bibr92-1073858418807887]; [@bibr140-1073858418807887]; [@bibr185-1073858418807887]; [@bibr204-1073858418807887]; [@bibr205-1073858418807887]). Advances in optical tools led to the discovery that these "state transitions" can be induced by activating only about a dozen glutatmatergic inputs to *distal* SPN dendrites (where they locally induce prolonged plateau potentials that can outlast the synaptic stimuli by hundreds of milliseconds), provided that they are convergent in time and space ([@bibr66-1073858418807887]; [@bibr162-1073858418807887]). Reliance on so few synapses (compared to original estimates of hundreds or more) greatly increases the computational capacity of SPNs ([@bibr26-1073858418807887]; [@bibr162-1073858418807887]) and suggests that the generation of dendritic plateaus may represent a mechanism by which meaningful synaptic *associations* can gate SPN output. What this means is that cortical activation of striatal output is not necessarily a linear process, as implied by the box-and-arrow model, and offers a clue as to how the striatum can begin to filter out cortical inputs that are potentially less relevant.

Striatal Afferents and Microcircuitry {#section4-1073858418807887}
=====================================

Both dSPNs and iSPNs receive highly convergent glutamatergic afferents from numerous cortical and subcortical regions. There is some evidence for preferential innervation of pathways, for example functional responses to cortical pyramidal tract neuron afferents are larger in dSPNs ([@bibr127-1073858418807887]; but see [@bibr56-1073858418807887]; [@bibr132-1073858418807887]; [@bibr169-1073858418807887]) and afferents originating from motor versus limbic-associated regions form biased connections on iSPNs and dSPNs, respectively ([@bibr199-1073858418807887]), but to date no inputs have been discovered that are SPN-type specific. This points out an important aspect of the model---though the direct and indirect pathways are depicted as discrete entities, there is tremendous overlap in their inputs and engagement.

Corticostriatal connections are roughly organized in a somatotopic fashion, with a consequence being that the striatum may connect diverse cortical regions to the thalamus via anatomically and functionally parallel (but we now know not fully independent) loops ([@bibr100-1073858418807887]; [@bibr152-1073858418807887]). Unlike structures such as the cortex and hippocampus, the striatum is not laminarly organized. However, postmortem histological analyses (such as acetylcholinesterase and mu opioid receptor expression) revealed that the striatum has a compartmental organization. About 10% of the striatum can be classified as striosomes (or patches), which are surrounded by the more prominent matrix compartment ([@bibr79-1073858418807887]; [@bibr96-1073858418807887]). Functionally, we are just starting to understand the full significance of such compartmentalization, but studies suggest that SPNs residing within striosomes mediate the establishment of psychostimulant-induced motor stereotypies and guide cost-benefit decision-making ([@bibr35-1073858418807887]; [@bibr76-1073858418807887]). Both afferents to and efferents from each compartment differ, with striosomes receiving more frontal cortex and limbic-associated inputs and directly innervating dopaminergic neurons in the substantia nigra pars compacta ([@bibr49-1073858418807887]; [@bibr77-1073858418807887]), though the degree of this segregation has recently been questioned ([@bibr182-1073858418807887]). Although not explicitly diagrammed in the classic box-and-arrow model, it is a conceptually straightforward addition. It is an important addition as well, as compartment-specific pathology occurs in both HD and PD ([@bibr48-1073858418807887]; [@bibr101-1073858418807887]).

By far the most prominent afferents to dorsal striatum SPNs are from the cortex and thalamus (in particular the centromedian (CM) and parafascicular (Pf) nuclei ([@bibr65-1073858418807887]; [@bibr67-1073858418807887]; [@bibr118-1073858418807887]; [@bibr206-1073858418807887]); though thalamic inputs were omitted from the original box-and-arrow model ([@bibr4-1073858418807887]; [@bibr55-1073858418807887]), they have since become a standard addition ([@bibr5-1073858418807887]; [@bibr184-1073858418807887]). Dysfunction of corticostriatal and thalamostriatal synaptic signaling is a hallmark of symptom progression in Huntington's disease, with dysregulation of glutamatergic synapses within the striatum occurring well before frank striatal and cortical cell death ([@bibr57-1073858418807887]; [@bibr164-1073858418807887]; [@bibr167-1073858418807887]; [@bibr217-1073858418807887]). These changes are complex, but overall there is a gradual synaptic disconnect between SPNs and their cortical inputs ([@bibr39-1073858418807887]; [@bibr167-1073858418807887]). Just as cell death is first observed in iSPNs and later dSPNs ([@bibr170-1073858418807887]), progressive SPN-type specific alterations in corticostriatal synaptic transmission occur as well, albeit in a complex manner ([@bibr7-1073858418807887]; [@bibr161-1073858418807887]). Overall such circuit changes are consistent with the early hyperkinetic symptoms of HD ([@bibr4-1073858418807887]; [@bibr7-1073858418807887]; [@bibr161-1073858418807887]; [@bibr217-1073858418807887]). Alterations in corticostriatal inputs are observed in PD models as well: dopamine depletion reduces the density of axospinous synapses formed by the cortex on iSPNs, while leaving those on dSPNs intact ([@bibr52-1073858418807887]). While this may at first seem counterintuitive in light of PD being a hypokinetic disorder, this spine loss likely reflects a compensatory attempt to counteract an acute increase in neuronal excitability resulting from diminished activation of D~2~Rs ([@bibr52-1073858418807887]; [@bibr72-1073858418807887]). *This illustrates an important caveat of the classic box-and-arrow model*: Relative changes in the activity of the direct and indirect pathways may reflect more than just a change in the balance of dSPN and iSPN activity (thickness of the arrows in the model), but a pathological bias in the cortical and subcortical network information that is being processed ([@bibr72-1073858418807887]).

While it is obvious that SPNs are major players in striatal circuit function and pathophysiology, there are also other types of striatal neurons, all of which are interneurons (see [Box 2](#boxed-text2-1073858418807887){ref-type="boxed-text"}). Among these are cholinergic interneurons (CINs), which had long been implicated in movement disorders, but like all other interneurons are not clearly integrated into the model ([@bibr15-1073858418807887]; [@bibr131-1073858418807887]) ([Fig. 1B](#fig1-1073858418807887){ref-type="fig"}). Anticholinergic therapy (administration of muscarinic receptor blockers) was widely used to treat striatum-associated disorders such as dystonia and PD before the advent of dopamine replacement therapy ([@bibr70-1073858418807887]; [@bibr110-1073858418807887]; [@bibr128-1073858418807887]; [@bibr159-1073858418807887]). Conversely, brain-penetrating acetylcholinesterase inhibitors were shown to reduce chorea in HD patients ([@bibr8-1073858418807887]). These clinical findings, in addition to experimental evidence that showed changes in the expression of dopaminergic and cholinergic markers in the striatum were inversely correlated in disease states, led to the famous striatal dopamine--acetylcholine imbalance hypothesis of BG-related movement disorders ([@bibr15-1073858418807887]; [@bibr53-1073858418807887]; [@bibr63-1073858418807887]; [@bibr131-1073858418807887]). CINs are the source of striatal acetylcholine (ACh) tone and must therefore be associated with the therapeutic effect of anticholinergics, but they are nevertheless glossed over in the model. This is a crucial issue to rectify, as it is now appreciated that cholinergic signaling (primarily through muscarinic receptors) mediated by CINs plays a profound role in modulating SPN excitability and synaptic transmission ([@bibr31-1073858418807887]; [@bibr54-1073858418807887]; [@bibr51-1073858418807887]; [@bibr90-1073858418807887]; [@bibr151-1073858418807887]). As in the case of SPNs, alterations in cortico- and thalamo-striatal inputs to CINs are observed in movement disorders such as PD and HD ([@bibr1-1073858418807887]; [@bibr105-1073858418807887]; [@bibr191-1073858418807887]). Whether these are homeostatic responses that aim to restore the dopamine--acetylcholine balance or maladaptive responses that exacerbate the imbalance is unclear. Furthermore, CINs have recently been shown to directly promote local dopamine release from SNc axonal terminals in the striatum (via a nicotinic acetylcholine receptor--mediated mechanism) ([@bibr195-1073858418807887]), highlighting the oversimplification and inherent caveats of the dopamine-acetylcholine imbalance hypothesis of striatal movement disorders.

###### 

Menagerie of striatal interneurons and GABAergic afferents.

In rodents, SPNs constitute more than 95% of striatal neurons. The remaining 2% to 4% of striatal neurons are composed of a single type of cholinergic interneuron (0.5%-1.5%) (see figure panel B) and several types of GABAergic interneurons (approximately 2%) (see figure panel C) ([@bibr11-1073858418807887]; [@bibr95-1073858418807887]; [@bibr146-1073858418807887]). These interneurons exert powerful influence over SPN dynamics both on a moment-by-moment time scale by activating pre- and postsynaptic receptors on SPNs and on a slower time scale by influencing the intrinsic excitability of SPNs and synaptic plasticity. Many of these interneurons are also targeted by dopamine fibers, as well as other intrinsic and extrinsic inputs ([@bibr11-1073858418807887]).

*Cholinergic interneurons (CINs)*. CINs are aspiny neurons with large (20-50 µm long) somata and overlapping axonal and dendritic arbors that span about a third of the striatum. CINs are autonomous pacemakers ([@bibr20-1073858418807887]), meaning that they possess intrinsic membrane currents that compel them to constantly depolarize to action potential threshold independently of their synaptic inputs ([@bibr19-1073858418807887]; [@bibr94-1073858418807887]; [@bibr144-1073858418807887]). This pacemaking action functions to maintain a perpetual ACh tone in the striatum. Because the axonal arbor of CINs is so extensive and space-filling, with release sites 1 µm apart, this perpetual tone is maintained throughout the whole volume of the striatum ([@bibr43-1073858418807887]; [@bibr60-1073858418807887]; [@bibr94-1073858418807887]). ACh release is further modulated by direct glutamatergic and dopaminergic inputs that regulate CIN activity (see figure panel B).

CINs are major modulators of SPN intrinsic excitability, as well as synaptic transmission and synaptic plasticity of SPN afferents. This is mediated by muscarinic ACh receptors (mAChRs), which can be found on axon terminals and all striatal types ([@bibr90-1073858418807887]). Activation of presynaptic M2 type mAChRs on cortical axon terminals curbs cortico-striatal synaptic transmission ([@bibr103-1073858418807887]; [@bibr151-1073858418807887]), whereas postsynaptic M~1~ mAChRs amplify transmission by momentarily increasing SPN excitability ([@bibr90-1073858418807887]).

ACh release in the striatum also activates nicotinic ACh receptors (nAChRs) located on various GABAergic interneurons. This mediates di-synaptic feedforward inhibition onto SPNs as well as di-synaptic feedback inhibition onto other CINs ([@bibr69-1073858418807887]; [@bibr187-1073858418807887]; [@bibr208-1073858418807887]). Furthermore, activation of presynaptic nAChRs on dopaminergic nigrostriatal axon terminals can directly induce dopamine release, independent of somatic activity ([@bibr195-1073858418807887]). Adding a final level of complexity, it is now known that dopamine fibers themselves can co-release GABA ([@bibr196-1073858418807887]), raising the possibility that fast di-synaptic inhibition from CINs to SPNs can be mediated by dopaminergic fibers, as well.

*Fast spiking interneurons (FSIs)*. The first and most widely studied GABAergic interneuron is the parvalbumin-positive (PV+) FSI that mediates strong feedforward cortical inhibition of SPNs ([@bibr69-1073858418807887]; [@bibr115-1073858418807887]). FSIs are hyperpolarized, have narrow action potentials and can fire at high rates often in a stuttering fashion ([@bibr115-1073858418807887]). These cells are one of the few examples of neurons in the mammalian CNS that exhibit class II [@bibr104-1073858418807887] excitability, meaning that when they transition from quiescence to firing they discharge at a finite minimal firing beneath which they cannot fire ([@bibr11-1073858418807887]). FSIs are interconnected by gap junctions ([@bibr120-1073858418807887]), similar to PV+ basket cells in the cortex, and can form a syncytium that synchronizes their inhibition throughout the striatum. FSIs also receive direct dopaminergic innervation (see figure panel C). It should be noted that despite initial conjectures, FSIs do not mediate the di-synaptic inhibition of SPNs by CINs.

*Plateau low-threshold spike interneurons (PLTSIs)*. Another GABAergic interneuron that mediates cortical feedforward inhibition is the neuropeptide-Y--positive/somatostatin-positive/nitric oxide synthase--positive (NPY+/SST+/NOS+) PLTSI. Its name summarizes its unique discharge properties in response to current injections and synaptic stimulation. Depolarizing current injections evoke a plateau potential and action potentials; depolarizing from a sufficiently hyperpolarized potential elicits a calcium-mediated low-threshold spike (LTS) that can also trigger sodium spikes ([@bibr115-1073858418807887]). PLTSIs are also autonomous pacemakers ([@bibr11-1073858418807887]; [@bibr17-1073858418807887]), and exhibit both single spiking and bursting discharge. It is likely that tonic activity is necessary for maintaining levels of the various neuromodulators and neuropeptides that PLTSIs release, which may be determined by the firing pattern ([@bibr17-1073858418807887]). The axonal arbors of PLTSIs are unbranched and sparse but can span the entire extent of the striatum. PLTSIs do not receive input from CINs and only about 20% receive inputs from FSI ([@bibr190-1073858418807887]). They do, however, receive dopaminergic inputs (see figure panel C).

*Calretinin-positive (CR+) interneurons*. CR+ interneurons were among the first GABAergic interneurons to be discovered, and in primates are composed of several subtypes that together outnumber FSIs and PLTSIs. Nevertheless, very little is known about them or their connectivity within the microcircuit, and only recently have articles begun to appear characterizing their activity *in vivo* ([@bibr78-1073858418807887]) (see figure panel C).

*Tyrosine hydroxylase--positive (TH+) interneurons*. In recent years, two new classes of GABAergic interneurons that receive both dopaminergic and cholinergic inputs have been rediscovered. TH+ interneurons are autonomously active, targeting PLTSIs and mediating cortical feedforward inhibition of SPNs ([@bibr212-1073858418807887]). One type of TH+ interneurons is currently unique in that it is the only type of GABAergic interneuron that is known to receive synaptic inhibition directly from SPNs ([@bibr108-1073858418807887]).

*Neuropeptide-Y--neurogliaform (NPY-NGF) interneurons*. Another class of recently described GABAergic neurons are NPY+ interneurons (sometimes referred to as neurogliaform interneurons) ([@bibr109-1073858418807887]). NPY-NGF interneurons do not express SST or NOS, nor do they display any of the physiological properties of the PLTSIs. Instead, they physiologically resemble SPNs: hyperpolarized at rest and require significant depolarization to fire. NPY-NGF interneurons have a dense axon that innervates a radius of approximately 0.5 mm and are reciprocally coupled with CINs. Accordingly, NPY-NGF neurons were found to mediate di-synaptic feedforward inhibition of SPNs by CINs, di-synaptic feedback inhibition among CINs ([@bibr69-1073858418807887]; [@bibr187-1073858418807887]) and even di-synaptic feed-forward *disinhibition* of SPNs by FSIs ([@bibr130-1073858418807887]). NPY-NGFs are coupled by gap junctions, which presumably helps to synchronize and amplify their inhibitory influence (see figure panel C). NPY-NGF interneurons, along with SPN axon collaterals, have been proposed to be uniquely positioned to modulate SPN dendritic plateau potentials and resulting spiking ([@bibr66-1073858418807887]).

*Other interneurons*. Our understanding of the complexity and heterogeneity of striatal interneurons is a work in progress, with new interneuron classes and connections still being discovered. For example, a recent study described a new GABAergic interneuron that only targets other interneurons, therefore affecting SPNs only by di-synaptic disinhibition, a novel concept in striatal microcircuitry ([@bibr9-1073858418807887]).

*Extrinsic inputs to the striatal microcircuitry*. The striatum receives extensive afferents from the cortex and SNc, but two important extrastriatal sources are not explicitly present in the original box-and-arrow model: the thalamus and globus pallidus (see figure panel D). The thalamus (e.g., CM and Pf) is an easy fix, and is the source of about 50% of the glutamatergic synapses onto SPNs ([@bibr67-1073858418807887]; [@bibr118-1073858418807887]). Pf inputs also impinge on CINs, FSIs, NPY-NGF interneurons and TH+ interneurons. PLTSIs are an exception in that they do not receive direct excitatory input from the Pf but receive powerful di-synaptic inhibition via TH+ interneurons ([@bibr10-1073858418807887]). The biophysics of synaptic transmission and plasticity are often different between cortico- and thalamo-striatal synapses and the direction of this difference depends on the identity of the postsynaptic neurons being targeted ([@bibr1-1073858418807887]; [@bibr62-1073858418807887]; [@bibr64-1073858418807887]).

While the existence of a pallidostriatal projection targeting interneurons has been known for decades ([@bibr24-1073858418807887]; [@bibr92-1073858418807887]), recent work has identified a subclass of pallidal neurons (termed "arkypallidal" neurons) that project back to SPNs, CINs and some of the GABAergic interneurons. These pallidostriatal neurons are molecularly and physiologically distinct from the majority of "prototypical" pallidal neurons that project to the STN and output nuclei of the BG ([@bibr84-1073858418807887]; [@bibr87-1073858418807887]; [@bibr102-1073858418807887]; [@bibr141-1073858418807887]).

Upon reflection on the current snapshot of striatal microcircuitry and its inputs and outputs (see figure) it seems at first sight overly complex. We are beginning to understand some of the rules of connectivity, but one thing is clear: reducing the whole striatal circuitry to a single box represented only by SPNs is no longer tenable.

![Striatal microcircuitry. (A) rendition of the striatum in original box-and-arrow model (with dSPN and iSPN collapsed to a single SPN), which includes only cortical and dopaminergic afferent inputs. (B) Cholinergic interneurons (CINs) are reciprocally ([@bibr47-1073858418807887]) connected to SPNs and terminate on dopamine axons. (C) GABAergic interneurons with their known connections to SPNs, reciprocal connections, and their cortical and dopaminergic inputs. (D) A current snapshot of known striatal circuitry, including afferent inputs from the GPe and the thalamic parafascicular nucleus (PfN). *Highlights*: (1) CINs and PLTSIs are tonically active autonomous pacemaker neurons; (2) CINs and TH interneurons are the only interneurons known to receive direct SPN input; (3) CINs and FSIs do not communicate with each other; 4) cortical and thalamic feedforward inhibition is mediated by a different subset of GABAergic interneurons. Abbreviations: see text.](10.1177_1073858418807887-fig6){#fig6-1073858418807887}

The remaining 2% of striatal neurons (in rodents, in primates the percentages are considerably higher) are composed of multiple types of GABAergic interneurons, several of which co-release other signaling molecules (see [Box 2](#boxed-text2-1073858418807887){ref-type="boxed-text"}) ([@bibr11-1073858418807887]; [@bibr95-1073858418807887]; [@bibr116-1073858418807887]; [@bibr146-1073858418807887]; [@bibr193-1073858418807887]). Because SPNs receive cortical innervation directly and because they (and only they) project outside the striatum, the first-approximation of the box-and-arrow model that neglects GABAergic interneurons seems reasonable ([Fig. 1A](#fig1-1073858418807887){ref-type="fig"}). However, we now know that these interneurons exert a powerful influence over SPN dynamics and synaptic inputs both on a moment-by-moment basis through fast synaptic transmission and on a slower time scale by influencing the intrinsic excitability of SPNs and synaptic plasticity ([@bibr11-1073858418807887]; [@bibr86-1073858418807887]; [@bibr122-1073858418807887]; [@bibr137-1073858418807887]; [@bibr139-1073858418807887]; [@bibr149-1073858418807887]; [@bibr150-1073858418807887]; [@bibr166-1073858418807887]; [@bibr201-1073858418807887]). Many interneurons are also targeted by dopamine fibers ([@bibr11-1073858418807887]), endowing them with the ability to shape how dopamine release modulates striatal output. The advent of optogenetics has led to a recent explosion in our understanding of the rich connectivity and functional consequences of local striatal microcircuitry (see [Box 2](#boxed-text2-1073858418807887){ref-type="boxed-text"}).

While pathological cholinergic signaling has been implicated in PD for decades ([@bibr15-1073858418807887]; [@bibr131-1073858418807887]), the idea that dysfunction of other interneurons fundamentally contributes to disease states has only recently garnered significant support. For example, although striatal GABAergic interneurons were once thought to be relatively spared from pathology in HD ([@bibr145-1073858418807887]), it is now known that the number of fast spiking interneurons (FSIs) is reduced in the striatum of symptomatic patients ([@bibr171-1073858418807887]). Furthermore, technological advances in both the refinement of mouse models and experimental techniques have discovered that the firing rate of "plateau low-threshold spike" interneurons (PLTSIs) and SPN responses to FSIs increase in symptomatic HD mice, consistent with overall observations of elevated intrastriatal GABAergic synaptic transmission ([@bibr38-1073858418807887]). Pathological alterations in connectivity have also been observed. FSIs rapidly increase their connectivity to iSPNs (not dSPNs) in the 6-OHDA mouse model of PD, a circuit alteration that has a net effect of enhancing synchrony among iSPNs ([@bibr85-1073858418807887]), and a phenomenon not readily predicted by the box-and-arrow model. Interneuron pathology occurs in other striatum-related movement disorders as well, such as Tourette Syndrome where there is a reduction in the number of FSIs and CINs ([@bibr113-1073858418807887]; [@bibr114-1073858418807887]), and a hamster model of dystonia where there is a reduction in the number of several types of GABAergic interneurons ([@bibr82-1073858418807887]; [@bibr172-1073858418807887]). Thus, the role of the striatum in movement disorders can no longer be fully appreciated without knowledge of the contribution of interneurons (see [Box 2](#boxed-text2-1073858418807887){ref-type="boxed-text"}).

Though interneurons undoubtedly account for a major component of intrastriatal inhibition, they are not the only source---SPNs also form collateral inhibitory connections with other SPNs. Importantly such inhibition occurs within and between direct and indirect pathway SPNs ([@bibr38-1073858418807887]; [@bibr99-1073858418807887]; [@bibr192-1073858418807887]). Under normal conditions this inhibition is biased, with the indirect pathway exerting a stronger inhibition over its counterpart than vice-versa ([@bibr192-1073858418807887]). Alterations in such collateral inhibition occur in mouse models of both PD and HD ([@bibr38-1073858418807887]; [@bibr192-1073858418807887]). Thus, pathway-specific striatal output is not as simple as dSPNs or iSPNs being activated---ongoing activity of SPNs shapes not only the output of their own pathway but that of their "opposing" pathway as well, a phenomenon not predicted by the box-and-arrow model and a concept that must be taken into account when referencing "balance" between the two pathways.

Synaptic Plasticity and Circuit Adaptation {#section5-1073858418807887}
==========================================

Perhaps the hardest thing to capture in a box-and-arrow diagram is the fact that neither the function of the boxes nor the strengths of the arrows are static entities. The dorsal striatum has been shown to be a key player in goal directed and habit learning ([@bibr97-1073858418807887]; [@bibr175-1073858418807887]; [@bibr174-1073858418807887]; [@bibr183-1073858418807887]; [@bibr214-1073858418807887]), the substrate of which is thought to be the ability to change the weights of physiologically relevant synapses in a way that will optimize behavioral outcomes. Both dSPNs and iSPNs have the capacity to bi-directionally change the weights of their synaptic inputs through long-term potentiation (LTP) and long-term depression (LTD), though the road to get to this conclusion was arduous ([@bibr32-1073858418807887]; [@bibr34-1073858418807887]; [@bibr125-1073858418807887]; [@bibr138-1073858418807887]; [@bibr176-1073858418807887]; [@bibr189-1073858418807887]). It is also not immediately obvious how the model can account for the development of symptoms and side effects over the course of disease treatment. For example, prolonged administration of levodopa or [L]{.smallcaps}-DOPA (a precursor to dopamine) to treat PD results in not only a diminishing therapeutic window of action, but also in the development of L-DOPA-induced dyskinesias (LIDs) ([@bibr16-1073858418807887]; [@bibr36-1073858418807887]). These examples underscore the notion that the striatum undergoes adaptive changes that contribute to both normal function and the progressive aspects of movement disorders, crucial concepts that a model must address.

Although LTP and LTD occur at the same types of striatal synapses, they are not expressed at the same loci within a synapse. LTP ultimately requires the insertion of AMPA receptors into the postsynaptic membrane, while LTD requires postsynaptic production of endocannabinoids that then retrogradely act on presynaptic CB1 receptors to reduce neurotransmitter release probability ([@bibr33-1073858418807887]; [@bibr126-1073858418807887]; [@bibr138-1073858418807887]; [@bibr189-1073858418807887]) (see [Box 3](#boxed-text3-1073858418807887){ref-type="boxed-text"}). This distinction is important, as it sets the groundwork for therapeutic target identification and design. Though the locus of expression differs, both LTP and LTD require combined pre- and postsynaptic activity, the timing of which can determine the sign of synaptic change ([@bibr75-1073858418807887]; [@bibr111-1073858418807887]; [@bibr150-1073858418807887]; [@bibr155-1073858418807887]; [@bibr176-1073858418807887]). Whether this timing is Hebbian (LTP is induced by presynaptic followed by postsynaptic activity and LTD is induced by the opposite ordering) or anti-Hebbian has traditionally been a controversial topic ([@bibr75-1073858418807887]; [@bibr155-1073858418807887]; [@bibr163-1073858418807887]; [@bibr176-1073858418807887]; [@bibr179-1073858418807887]), but the reasons for this have begun to surface. Basal levels and timed transient elevations of dopamine, engagement of local GABAergic microcircuitry, the degree of cytosolic calcium elevation achieved at the synapse by paired pre- and post- synaptic activity, repetition of stimulation, SPN-type, and even the rapid conversion of LTD to LTP when particular circuit-level conditions are met all determine the sign of plasticity that is achieved by paired pre- and postsynaptic activity ([@bibr150-1073858418807887]; [@bibr163-1073858418807887]; [@bibr176-1073858418807887]; [@bibr179-1073858418807887]; [@bibr180-1073858418807887]; [@bibr213-1073858418807887]). Though the details of how each of these parameters contributes to spike timing dependent plasticity are beyond the scope of this review, we note these complexities to illustrate the myriad factors that determine the "weight" of each arrow in the box-and-arrow model, particularly under pathological conditions.

###### 

Striatal plasticity.

Corticostriatal LTP and LTD each involve their own sets of "key players." For LTP, these include engagement of *N*-methyl-[d]{.smallcaps}-aspartate receptors (NMDARs), a G-protein coupled receptor positively linked to adenylyl cyclase (AC), postsynaptic tyrosine-related kinase B receptors (TrkBRs), in some scenarios M~1~-type muscarinic receptors and, more recently described, calcium-permeable AMPA receptors ([@bibr34-1073858418807887]; [@bibr31-1073858418807887]; [@bibr112-1073858418807887]; [@bibr161-1073858418807887]; [@bibr176-1073858418807887]; [@bibr180-1073858418807887]; [@bibr189-1073858418807887]). For LTD these include engagement of postsynaptic metabotropic glutamate receptor 5 (mGluR5), a GPCR negatively linked to AC, postsynaptic L-type voltage gated calcium channels (L-VGCCs) and presynaptic CB1 cannabinoid receptors ([@bibr2-1073858418807887]; [@bibr3-1073858418807887]; [@bibr124-1073858418807887], [@bibr125-1073858418807887]; [@bibr138-1073858418807887]; [@bibr163-1073858418807887]; [@bibr176-1073858418807887]; [@bibr189-1073858418807887]). Both forms of plasticity require postsynaptic depolarization, but for different reasons: to remove Mg^2+^ block of NMDARs for LTP and to engage L-type voltage gated calcium channels for LTD. The culmination of these postsynaptic cascades is to promote the insertion of AMPA receptors (AMPARs) into the postsynaptic density for LTP and the production of endocannabinoids for LTD. While on the surface LTP and LTD appear to be flip sides of the same coin (strengthening vs. weakening a synapse), the way they are *expressed* is quite different: LTP is expressed postsynaptically, as an increase in AMPAR density, while LTD is expressed presynaptically (via trans-synaptic diffusion of endocannabinoids), as a CB1 receptor-mediated reduction in neurotransmitter release probability ([@bibr138-1073858418807887]; [@bibr189-1073858418807887]). In SPNs, endocannabinoid-dependent LTD is also restricted to cortical inputs, as thalamic inputs lack sufficient expression of the requisite presynaptic CB1 receptors ([@bibr210-1073858418807887]). It is worth noting that mGluR-mediated endocannabinoid-dependent depression can also occur at GABAergic synapses in the striatum and has been reported to be pathologically elevated in mouse models of HD ([@bibr3-1073858418807887]; [@bibr68-1073858418807887]). Other forms of LTD have more recently been discovered, such as variants of presynaptically expressed LTD that are mediated by presynaptic 5-HT1b ([@bibr143-1073858418807887]) and opioid ([@bibr14-1073858418807887]) receptors, postsynaptically expressed LTD mediated by nitric oxide ([@bibr166-1073858418807887]), and mGluR-mediated postsynaptic AMPAR internalization that can be unmasked under pathological conditions ([@bibr200-1073858418807887]), but this is beyond the scope of the review. It has now become apparent that LTP and LTD induction can be conceptualized as opposing processes ([@bibr176-1073858418807887]). Recent work has shed light on how this can occur, and how dopamine plays a central role in determining the sign of plasticity. Both iSPNs and dSPNs express Regulator of G-protein Signaling 4 (RGS4), a signaling molecule that inhibits Gq-linked GPCR activity. As mGluR5 is a Gq-linked GPCR, RGS4 activity prevents mGluR5-dependent endocannabinoid production and LTD ([@bibr134-1073858418807887]). Because of its cAMP-dependence, RGS4 activity is increased by D~1~- or A2a- receptor activation and decreased by D~2~- or M~4~- receptor activation ([@bibr134-1073858418807887]; [@bibr177-1073858418807887]). As such, mGluR5-mediated LTD will be inhibited by activation of D~1~ or A2a receptors and disinhibited by activation of D~2~ or M~4~ receptors. As LTD is impaired after dopamine depletion in mice, inhibition of RGS4 has been implicated as a potential therapeutic strategy for the treatment of PD ([@bibr134-1073858418807887]).

![Synaptic plasticity. Pre- and postsynaptic signaling cascades responsible for long-term potentiation/depression (LTP/LTD). Abbreviations: MEK-ERK, mitogen-activated protein kinase kinase (MEK)--extracellular signal-regulated kinase (ERK); AKT, protein kinase B; PLC, phospholipase C; PI3K, phosphoinositide 3-kinase; CICR, calcium-induced calcium release; PLD, phospholipase D; eCB, endocannabinoid; µ/δOR, µ/δ opioid receptor; 5-HT1bR, 5-HT type 1b receptor; other abbreviations as in text.](10.1177_1073858418807887-fig7){#fig7-1073858418807887}

While both dSPNs and iSPNs support LTP and LTD, the neuromodulators associated with the induction of each differs between the two neuron populations (see [Box 3](#boxed-text3-1073858418807887){ref-type="boxed-text"}). The reason is readily apparent in the box-and-arrow model: D~1~Rs (which promote LTP) are only expressed in dSPNs, while D~2~Rs (which promote LTD) are only expressed in iSPNs ([@bibr81-1073858418807887]; [@bibr80-1073858418807887]). This leads to a conceptual problem: how do both dSPNs and iSPNs display bidirectional plasticity if D~1~ and D~2~ receptors are segregated in the two neuron populations? Groundbreaking work by the Surmeier group solved the mystery of how this can happen. Dopamine receptors are not the only neuromodulator receptors that show SPN-type subunit specificity. Though iSPNs do not express D~1~Rs, they do express A2a-type adenosine receptors, which engage the same G~olf~-linked G-protein coupled receptor (GPCR) signaling cascade and promote LTP in the same way D~1~Rs do in dSPNs ([@bibr176-1073858418807887]). Similarly, while dSPNs do not express D~2~Rs they do express M~4~-type muscarinic receptors (M~4~Rs), which feed into the same G~i~-linked GPCR signaling cascade and promote LTD in the same way D~2~Rs do in iSPNs ([@bibr177-1073858418807887]). Though this endows both SPN populations with the ability to support bidirectional plasticity, two things should be noted: (1) Only one form of plasticity in each SPN type may *directly* reflect stored information that was encoded by behaviorally relevant elevations in *dopamine* and (2) disease-related impairments in dopamine release will have opposite effects on the sign of plasticity in the direct and indirect pathways. Indeed, the latter point was demonstrated by Shen and others (2008), who showed that dopamine depletion caused paired spike patterns that normally induce LTP to yield LTD in dSPNs and paired spike patterns that normally induce LTD to yield LTP in iSPNs. This phenomenon is consistent with the box-and-arrow diagram used to explain PD: weakening of the direct pathway and strengthening of the indirect pathway. But the way in which this happens differs- in the model pathway-specific output is globally elevated or reduced, while the above finding suggests that such changes may have a synapse-specific underpinning. This is an important point, as not all glutamatergic inputs to the striatum support the same forms of LTP and LTD ([@bibr161-1073858418807887]; [@bibr210-1073858418807887]), adding a layer of network-specificity not afforded by the original model.

Impaired ability to alter synaptic strength in a physiological meaningful way can contribute to both hypokinetic (e.g., PD) and hyperkinetic (e.g., HD and LIDs) disorders, depending on the mechanism and location of the pathology. In a seminal study, Kreitzer and Malenka ([@bibr125-1073858418807887]) demonstrated that corticostriatal LTD is lost in iSPNs in a mouse model of PD, and pharmacologically rescuing LTD at these synapses (by increasing striatal D~2~ receptor activation and reducing endocannabinoid degradation) also ameliorates behavioral deficits. Recent work in mice containing mutant variants of the huntingtin gene demonstrated that corticostriatal LTP is selectively lost in iSPNs early on in disease progression (due to impaired BDNF signaling) ([@bibr161-1073858418807887]). While impaired LTP at corticostriatal synapses on iSPNs may contribute to a hyperkinetic symptomatology in HD, pathologically excessive LTP at dSPNs may underlie hyperkinetic behaviors in LIDs ([@bibr158-1073858418807887]; [@bibr177-1073858418807887]). This is likely due to periods of prolonged activation of D~1~Rs following L-DOPA administrations ([@bibr36-1073858418807887]). Both excessive LTP in dSPNs (in mice) and dyskinetic behaviors (in mice and nonhuman primates) can be corrected by enhancing activation of M~4~ receptors (which counterbalances the D~1~R mediated increase in PKA activity and promotes LTD; see [Box 3](#boxed-text3-1073858418807887){ref-type="boxed-text"}), offering an elegant way to alleviate dyskinetic behaviors without sacrificing the benefits of L-DOPA treatment ([@bibr177-1073858418807887]).

Not all forms of plasticity involve LTP and LTD. Neurons employ homeostatic mechanisms to adapt to normal and pathological alterations in network activity and their local environment ([@bibr30-1073858418807887]; [@bibr198-1073858418807887]; [@bibr215-1073858418807887]; [@bibr216-1073858418807887]). Mounting evidence suggests that many striatal circuit pathologies underlying PD stem from maladaptive homeostatic adaptations. Acute activation of D~1~Rs modulates a constellation of postsynaptic conductances that ultimately increases the excitability of dSPNs, while acute activation of D~2~Rs leads to a reduction in iSPN excitability ([@bibr80-1073858418807887]). After chronic dopamine depletion, however, SPNs adapt to the lack of excitatory or inhibitory modulation by increasing intrinsic excitability in dSPNs and decreasing it in iSPNs ([@bibr72-1073858418807887]). Prolonged L-DOPA administration induces a further set of complex functional and morphological homeostatic adaptations that include pruning and addition of specific classes of synaptic inputs to SPNs ([@bibr71-1073858418807887]; [@bibr72-1073858418807887]; [@bibr73-1073858418807887]; [@bibr186-1073858418807887]; [@bibr216-1073858418807887]). Though the etiology of such changes may be driven by an attempt to retain a degree of normalcy in terms of activity, the changes in network connectivity driven by synapse pruning and formation may themselves contribute to pathology and the circuit-underpinnings of LIDs ([@bibr72-1073858418807887]). Such homeostatic adaptations to diminished or elevated dopaminergic tone highlight the inherent limitation of a static circuit model.

Summary {#section6-1073858418807887}
=======

The classic box-and-arrow model was a transformative advance that still holds enormous utility, but more recent advances in the field have shed light on its limitations. Decades of research have since uncovered complexities in intrastriatal processing that shape the engagement and patterning of the direct and indirect pathways, including antagonistic interactions between the pathways themselves. It has also become apparent that the striatum (and BG in general) is not a static network but is rather flexible and adaptive---pathophysiology is often the result of aberrant synchronous/rhythmic activity, synaptic plasticity or maladaptive compensations rather than generalized increases and decreases in the "strengths" of striatal output arrows ([Fig. 4](#fig4-1073858418807887){ref-type="fig"}). Representing these attributes in a two-dimensional diagram is not a straightforward task but recognizing them is crucial in the search for the pathological loci that should be targeted to treat complex movement disorders while avoiding deleterious side effects.

![Current models of striatal circuit pathology in PD and HD. Diagrams focus on functional and anatomical microcircuit alterations; simplified and non-exhaustive due to space constraints. A. Circuit pathologies in PD. B. Circuit pathologies in early symptomatic HD, pre-SPN death. The diagrams highlight unique and complex constellations of striatal circuit alterations (not just elevated direct and indirect pathways) that sum to yield disease symptomatology. Loci of circuit alterations are highlighted in red/green and labeled. Abbreviations: see text.](10.1177_1073858418807887-fig4){#fig4-1073858418807887}
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